Vis børsmeldingen
announcements by Thor Medical ASA (the “Company”) on 3 September 2026 regarding
the successful completion of a private placement of new shares to be issued by
the Company (the “Private Placement”) and a retail offering through Nordnet (the
“Retail Offering”).
Reference is also made to the share lending agreement entered into by and
between the Company, its shareholder Scatec Innovation AS as share lender and
Arctic Securities AS and ABG Sundal Collier ASA as managers (the “Managers”), to
facilitate delivery-versus-payment settlement in the Private Placement and the
Retail Offering (the “Share Lending Agreement”).
Today, following registration of the share capital increases pertaining to the
Private Placement and the Retail Offering, the Managers will redeliver
57,291,667 new shares in the Company to Scatec Innovation AS pursuant to the
Share Lending Agreement.
Following the effectuation of the redelivery of 57,291,667 new shares in the
Company and the delivery of 5,208,333 new shares allocated to Scatec Innovation
AS in the Private Placement, Scatec Innovation AS’ holding of shares in the
Company will be 87,326,613, equivalent to approx. 20.67% of the issued share
capital and votes. Consequently, Scatec Innovation AS will cross above the 10%,
15% and 20% thresholds pursuant to section 4-2 (1) and (3) of the Norwegian
Securities Trading Act.
This announcement is published in accordance with section 4-2 of the Norwegian
Securities Trading Act.
Contacts
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05
724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company’s proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies. Thor Medical’s product portfolio
includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and
radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical’s
production process requires neither irradiation nor nuclear reactors, providing
significant cost advantages while minimizing radioactive waste. Guided by its
vision to become a world-leading enabler for targeted cancer therapies, Thor
Medical is committed to improving millions of lives by powering the next
generation of precision cancer treatment with high-purity isotopes. Thor Medical
is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under
the ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19059000/17096/Download%20announc
ement%20as%20PDF.pdf
Kilde
